Inogen (INGN) | Financial Analysis & Statements
Inogen Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
81.7M
Gross Profit
35.2M
43.12%
Operating Income
-9.3M
-11.39%
Net Income
-7.1M
-8.72%
Balance Sheet Metrics
Total Assets
298.6M
Total Liabilities
106.4M
Shareholders Equity
192.2M
Debt to Equity
0.55
Cash Flow Metrics
Operating Cash Flow
-3.2M
Free Cash Flow
-3.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Inogen Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 348.7M | 335.7M | 315.7M | 377.2M | 358.0M |
| Cost of Goods Sold | 194.4M | 181.0M | 189.0M | 223.7M | 181.5M |
| Gross Profit | 154.3M | 154.7M | 126.7M | 153.5M | 176.5M |
| Gross Margin % | 44.2% | 46.1% | 40.1% | 40.7% | 49.3% |
| Operating Expenses | |||||
| Research & Development | 19.4M | 21.6M | 20.8M | 21.9M | 16.6M |
| Selling, General & Administrative | 165.1M | 175.6M | 182.4M | 164.7M | 150.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 184.5M | 197.3M | 203.2M | 186.6M | 167.2M |
| Operating Income | -30.2M | -42.5M | -76.5M | -33.1M | 9.2M |
| Operating Margin % | -8.7% | -12.7% | -24.2% | -8.8% | 2.6% |
| Non-Operating Items | |||||
| Interest Income | 4.4M | 5.2M | 6.6M | 2.8M | 129.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 2.4M | 850.0K | -32.4M | -53.0M | -710.0K |
| Pre-tax Income | -23.4M | -36.5M | -102.3M | -83.3M | 8.7M |
| Income Tax | -632.0K | -588.0K | 105.0K | 504.0K | 15.0M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 173.1% |
| Net Income | -22.7M | -35.9M | -102.4M | -83.8M | -6.3M |
| Net Margin % | -6.5% | -10.7% | -32.5% | -22.2% | -1.8% |
| Key Metrics | |||||
| EBITDA | -9.5M | -21.5M | -25.4M | 42.6M | 30.9M |
| EPS (Basic) | $-0.86 | $-1.52 | $-4.42 | $-3.67 | $-0.28 |
| EPS (Diluted) | $-0.86 | $-1.52 | $-4.42 | $-3.67 | $-0.28 |
| Basic Shares Outstanding | 26601652 | 23654395 | 23176098 | 22852571 | 22490027 |
| Diluted Shares Outstanding | 26601652 | 23654395 | 23176098 | 22852571 | 22490027 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Inogen Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 103.7M | 113.8M | 125.5M | 187.0M | 235.5M |
| Short-term Investments | 15.8M | 0 | 3.0M | 0 | 10.0M |
| Accounts Receivable | 38.9M | 29.6M | 42.2M | 62.7M | 24.5M |
| Inventory | 26.0M | 24.8M | 21.8M | 34.1M | 31.9M |
| Other Current Assets | 12.6M | 13.1M | 13.8M | 19.2M | 26.0M |
| Total Current Assets | 198.3M | 185.5M | 207.1M | 304.6M | 329.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 101.8M | 107.4M | 118.5M | 116.8M | 96.0M |
| Goodwill | 52.2M | 49.4M | 54.7M | 65.9M | 126.1M |
| Intangible Assets | 30.8M | 30.5M | 34.6M | 177.0K | 60.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 6.0M | 8.1M | 3.8M | 2.4M | 3.4M |
| Total Non-Current Assets | 100.3M | 110.7M | 119.1M | 100.4M | 160.3M |
| Total Assets | 298.6M | 296.2M | 326.2M | 405.0M | 489.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 20.3M | 16.6M | 13.5M | 18.2M | 10.3M |
| Short-term Debt | 3.2M | 2.8M | 3.7M | 3.5M | 3.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | 13.0M | 10.0M | - | - |
| Total Current Liabilities | 63.5M | 76.7M | 72.5M | 65.3M | 61.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 14.3M | 16.6M | 18.3M | 19.8M | 23.3M |
| Deferred Tax Liabilities | 6.7M | 6.9M | 8.5M | 0 | 0 |
| Other Non-Current Liabilities | - | - | - | - | 15.4M |
| Total Non-Current Liabilities | 42.9M | 45.6M | 48.9M | 42.3M | 57.8M |
| Total Liabilities | 106.4M | 122.3M | 121.4M | 107.6M | 119.3M |
| Equity | |||||
| Common Stock | 27.0K | 24.0K | 23.0K | 23.0K | 23.0K |
| Retained Earnings | -175.6M | -152.8M | -116.9M | -14.5M | 69.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 192.2M | 173.9M | 204.8M | 297.4M | 370.2M |
| Key Metrics | |||||
| Total Debt | 17.5M | 19.4M | 21.9M | 23.3M | 26.7M |
| Working Capital | 134.8M | 108.8M | 134.6M | 239.3M | 267.7M |
Balance Sheet Composition
Inogen Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -22.7M | -35.9M | -102.4M | -83.8M | -6.3M |
| Depreciation & Amortization | 20.7M | 21.0M | 18.2M | 23.5M | 21.6M |
| Stock-Based Compensation | 8.0M | 7.4M | 7.4M | 12.3M | 10.9M |
| Working Capital Changes | -21.5M | -13.1M | 9.2M | -45.3M | -21.1M |
| Operating Cash Flow | -16.2M | -18.3M | -59.1M | -108.7M | 8.0M |
| Investing Activities | |||||
| Capital Expenditures | -10.4M | -15.0M | -26.5M | -21.2M | -23.9M |
| Acquisitions | 0 | 0 | -29.6M | 0 | 0 |
| Investment Purchases | -29.8M | -32.7M | -26.9M | 0 | -10.0M |
| Investment Sales | 14.0M | 35.5M | 24.0M | 10.0M | 19.3M |
| Investing Cash Flow | -26.2M | -11.9M | -58.8M | -10.9M | -14.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 23.2M | -546.0K | -518.0K | -1.4M | -647.0K |
| Free Cash Flow | -21.6M | -11.2M | -30.2M | -58.8M | -434.0K |
| Net Change in Cash | -19.2M | -30.8M | -118.4M | -120.9M | -7.1M |
Cash Flow Trend
Inogen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-8.14
Forward P/E
-22.45
Price to Book
0.99
Price to Sales
0.54
PEG Ratio
0.22
Profitability Ratios
Profit Margin
-6.52%
Operating Margin
-12.21%
Return on Equity
-12.43%
Return on Assets
-6.35%
Financial Health
Current Ratio
3.12
Debt to Equity
9.09
Beta
1.70
Per Share Data
EPS (TTM)
$-0.86
Book Value per Share
$7.06
Revenue per Share
$13.11
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| INGN | 190.4M | -8.14 | 0.99 | -12.43% | -6.52% | 9.09 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Monogram | 244.2M | -13.04 | 25.10 | -228.82% | 0.00% | 3.44 |
| Sight Sciences | 237.2M | - | 3.66 | -50.74% | -49.67% | 63.77 |
| Nevro | 224.1M | 144.40 | 0.96 | -43.29% | -27.77% | 108.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.






